Who are Vistagen Therapeutics, Inc.'s main suppliers?

Vistagen Therapeutics, Inc. (VTGN) key suppliers include: Abbott Laboratories, Abbott Laboratories, Johnson & Johnson, Johnson & Johnson, Eli Lilly and Company and 3 more. View the full supplier network at chainsifter.com/chain/VTGN.

Who are Vistagen Therapeutics, Inc.'s major customers?

Vistagen Therapeutics, Inc. (VTGN) key customers include: AFFAMED-THERAPEUTICS-INC, FUJI-PHARMA-CO-LTD, Abbott Laboratories, Abbott Laboratories, Johnson & Johnson and 6 more. View the full customer network at chainsifter.com/chain/VTGN.

What sector is Vistagen Therapeutics, Inc. in?

Vistagen Therapeutics, Inc. (VTGN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Vistagen Therapeutics, Inc. Suppliers, Customers & Supply Chain (VTGN)

8Suppliers

11Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Vistagen Therapeutics, Inc. (VTGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

4Distinct source URLs

6High confidence

0.764Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Vistagen Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ABT	Abbott Laboratories	72%	ipated severity or frequency, or problems with the facility where our product candidates are manufactured, a regulatory agency may impose restrictions on our product candidates, the manufacturer or u…
ABT	Abbott Laboratories	72%	Reciprocal relationship from ABT graph: Reciprocal relationship from VTGN graph: ipated severity or frequency, or problems with the facility where our product candidates are manufactured, a regulator…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: consideration for the Exclusive Negot…
JNJ	Johnson & Johnson	72%	consideration for the Exclusive Negotiation Period, we received from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: consideration for the Exclusive Negot…
LLY	Eli Lilly and Company	72%	consideration for the Exclusive Negotiation Period, we received from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third …
ORANY	ORANY	72%	of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or a…

Vistagen Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
AFFAMED-THERAPEUTICS-INC	AFFAMED-THERAPEUTICS-INC	92%	Sublicense and other revenue consist of revenue recognized under our License and Collaboration Agreement with AffaMed Therapeutics, Inc. ( the Affamed Agreement )
FUJI-PHARMA-CO-LTD	FUJI-PHARMA-CO-LTD	92%	Sublicense and other revenue consist of revenue recognized under our License and Collaboration Agreement with AffaMed Therapeutics, Inc. ( the Affamed Agreement ) and our Exclusive Negotiation Agreem…
ABT	Abbott Laboratories	72%	ipated severity or frequency, or problems with the facility where our product candidates are manufactured, a regulatory agency may impose restrictions on our product candidates, the manufacturer or u…
ABT	Abbott Laboratories	72%	Reciprocal relationship from ABT graph: Reciprocal relationship from VTGN graph: ipated severity or frequency, or problems with the facility where our product candidates are manufactured, a regulator…
JNJ	Johnson & Johnson	72%	consideration for the Exclusive Negotiation Period, we received from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: consideration for the Exclusive Negotiation Period, we received from Fuji Pharma a payment of $1.5 million (Purchase P…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from LLY grap…
LLY	Eli Lilly and Company	72%	consideration for the Exclusive Negotiation Period, we received from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: al of completing its review of 90…
ORANY	ORANY	72%	al of completing its review of 90% of all applications within ten months from the submission receipt date. Such deadlines are referred to as the PDUFA date. The review process and the PDUFA goal date…
PHERIN-PHARMACEUTICALS-INC	PHERIN-PHARMACEUTICALS-INC	62%	he announcement of top-line results from our PALISADE-3 clinical trial. We expect general and administrative expenses to continue to decrease in future periods as a result of these cash preservation …

Vistagen Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VTGN-DEBT-13458	Warrants outstanding: 9275858	90%	xbrl warrant detail from xbrl 2025-07-31.
VTGN-DEBT	Debt stack $1.4M	90%	Market cache reports total debt of $1.4M.
VTGN-DEBT-13459	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2017-03-31.

Vistagen Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vistagen Therapeutics, Inc..

Vistagen Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
VTGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 59 tracked holders.

Vistagen Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
LLY	Eli Lilly and Company	100.00	1	['customer', 'supplier']
JNJ	Johnson & Johnson	100.00	1	['customer', 'supplier']
ABT	Abbott Laboratories	100.00	1	['customer', 'supplier']
ORANY	ORANGE	100.00	1	['customer', 'supplier']
BLRX	BioLineRx Ltd.	50.00	2
BLTE	Belite Bio, Inc	50.00	2
BCDRF	Banco Santander, S.A.	50.00	2
BLLN	BillionToOne, Inc.	50.00	2
BLNK	Blink Charging Co.	50.00	2
AMXOF	AMERICA MOVIL SAB DE CV/	50.00	2
BFRIW	Biofrontera Inc.	50.00	2
AMZE	Amaze Holdings, Inc.	50.00	2
CTNM	Contineum Therapeutics, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
ANIK	Anika Therapeutics, Inc.	50.00	2
BFRGW	BullFrog AI Holdings, Inc.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
CMCM	Cheetah Mobile Inc.	50.00	2
ARQQW	Arqit Quantum Inc.	50.00	2

Vistagen Therapeutics, Inc. Supply Chain